Check for updates

RESEARCH ARTICLE

Hyperthermic intraperitoneal chemoperfusion with high dose oxaliplatin: Influence of perfusion temperature on postoperative outcome and survival [version 1; peer review: 1 approved, 1 approved with reservations, 1 not approved]

Johanna Verhulst

Independent Researcher, Karel Oomsstraat 57, Antwerpen, 2018, Belgium

V1 First published: 03 Sep 2013, 2:179
<https://doi.org/10.12688/f1000research.2-179.v1>

Latest published: 16 Oct 2015, 2:179
<https://doi.org/10.12688/f1000research.2-179.v2>

Abstract

Introduction: Hyperthermic intraperitoneal chemotherapy (HIPEC) is becoming a standard therapy in the treatment of peritoneal carcinomatosis (PC). Compared to systemic chemotherapy, HIPEC improves survival in patients with PC. This therapy has high morbidity rates (up to 41%). In vitro it has been demonstrated that hyperthermia has a toxic effect on malign cells. However, hyperthermia also affects normal tissue. To my knowledge, any additional effect of hyperthermia combined with chemotherapy has never been demonstrated in a clinical setting. In this study, the effects of hyperthermia on outcome and survival were analyzed.

Methods: Patients with PC from any origin who were treated with HIPEC were included in this retrospective, non-randomized study. Data on patient characteristics, tumor characteristics, features of the surgery and postoperative complications were extracted from patient files. Models predicting time to removal of nasogastric tube (TRNT), post-operative major complications, the occurrence of anastomotic leaks and post-operative survival were built, using negative binomial regression, logistic regression or Cox proportional hazards regression as appropriate.

Results: 138 patients treated with HIPEC were included. Maximal temperature during the operation was not statistically significantly associated with anastomotic leaks or post-operative major complications. Maximal temperature during the operation was negatively associated with post-operative survival ($P=0.01$).

Conclusion: The results suggest that hyperthermia may negatively affect survival in patients who are treated with HIPEC for PC of various origins. This study has the classical limitations of a retrospective study. Therefore, randomized trials are required to confirm the results.

Open Peer Review

Approval Status

	1	2	3
version 2 (revision) 16 Oct 2015		view	view

version 1 03 Sep 2013	view	view	view

1. **David L Morris**, University of New South Wales, NSW, Australia
2. **Pompiliu Piso**, University of Regensburg, Regensburg, Germany
3. **Shigeki Kusamura**, Fondazione IRCCS Istituto Nazionale Tumori Milano, Milan, Italy

Any reports and responses or comments on the article can be found at the end of the article.

Corresponding author: Johanna Verhulst (johanna_verhulst@yahoo.com)

Competing interests: No relevant competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2013 Verhulst J. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the [Creative Commons Zero "No rights reserved" data waiver](#) (CC0 1.0 Public domain dedication).

How to cite this article: Verhulst J. **Hyperthermic intraperitoneal chemoperfusion with high dose oxaliplatin: Influence of perfusion temperature on postoperative outcome and survival [version 1; peer review: 1 approved, 1 approved with reservations, 1 not approved]** F1000Research 2013, 2:179 <https://doi.org/10.12688/f1000research.2-179.v1>

First published: 03 Sep 2013, 2:179 <https://doi.org/10.12688/f1000research.2-179.v1>

Editorial note:

The author of this article has informed *F1000Research* that the above study was set up in response to a request from her former supervisor to investigate the effects of perfusion temperature on post-operative morbidity and mortality after hyperthermic intraperitoneal chemoperfusion. The author has informed *F1000Research* that due to a disagreement over publication of these results with her former supervisor she resigned from her post.

The author has informed *F1000Research* that she asked her medical ethical body for advice on the situation. On 12 June 2013, the author presented the case to this regulatory body. The author has notified *F1000Research* that she was informed on 20th June by such body that the right to publish is a universally acknowledged right and that she was free to publish the results of the study if she felt it appropriate.

3/4/2014: An investigation into the ownership of the data used in this research has been conducted by the Commission for Scientific Integrity at Ghent University. This is now complete and a statement suggested by the Commission regarding the data will be added to a new version of this article.

Introduction

Peritoneal carcinomatosis (PC) occurs in 5% of patients with colorectal carcinoma and in patients with FIGO (International Federation of Gynecology and Obstetrics) stage III and IV ovarian cancer¹. PC can occur synchronous with the primary tumor or as a relapse (metachronous). Survival rates in patients with PC are rather poor. The median survival with standard chemotherapy is 50 and 23 months for PC of ovarian and colorectal origin, respectively^{2,3}. When treated with hyperthermic intraperitoneal chemotherapy (HIPEC), survival rates of patients with PC of ovarian and colorectal origin increased to 66 and 30 months, respectively^{2,4}.

There is an increasing interest in the use of locoregional antineoplastic drug therapy in patients with PC. The benefit of intraperitoneal chemotherapy arises from the existence of a peritoneal-plasma barrier. This barrier allows the local administration of higher doses of chemotherapy while minimizing systemic side effects⁵. Cytotoxic drugs penetrate only a few millimeters into tumor tissue⁶. To improve penetration, HIPEC is combined with cytoreductive surgery, where the tumor mass is decreased as much as possible before the administration of chemotherapy.

Oxaliplatin is recognized as a standard adjuvant treatment in colorectal cancer⁷. Promising results were also demonstrated in ovarian cancer, gastric cancer and malignant mesothelioma^{8–10}. Oxaliplatin is rapidly absorbed intracellularly, as a result of its lipophilic structure¹¹. Combined, these features make oxaliplatin a logical choice for local administration.

Hyperthermic perfusions are used because hyperthermia stimulates apoptosis in tumor cells^{12–14}. Recently it was demonstrated that hyperthermia increases the peritoneal oxaliplatin concentration while reducing systemic absorption¹⁵. However hyperthermia also induces apoptosis in normal cells¹⁴ and affects the healing of anastomosis^{16–18}. Furthermore, it was demonstrated in a rat model of PC of colorectal origin that hyperthermia did not increase survival compared to normothermic intraperitoneal treatment¹⁹. To my knowledge, any additional effect of hyperthermia combined with

intraperitoneal chemotherapy compared to intraperitoneal chemotherapy alone has not been demonstrated.

Although in a recent trial the preoperative level of functioning was reached three to six months after surgery²⁰, the morbidity rates described in patients after HIPEC are rather high (up to 41%)²¹. The role of hyperthermia in the improved survival is not clear, and it is possible that the morbidity may be (partially) a result of the hyperthermia.

The aim of this study was to identify the impact of the temperature of the perfusate on post-operative ileus, major post-operative complications, the occurrence of anastomotic leaks and post-operative survival.

Materials and methods

This is a retrospective, non-randomized study. By the retrospective and anonymised nature of the study, no informed consent of the patients was required. The study included patients from one university hospital. All patients that presented with resectable PC from any origin were eligible for inclusion. Patients with primary PC were included, as well as patients with metachronous PC. Electronic patient files were reviewed and the following data were extracted: age at the time of the operation, gender, body mass index (BMI), duration of anesthesia, time to removal of nasogastric tube (TRNT, measured from the day of operation), duration of stay in intensive care unit (ICU), duration of total hospital stay, 30-days mortality, post-operative complications, maximal perfusate temperature (Tmax), and area under the temperature curve (AUC) as a measure of total temperature. Analyses of biochemistry and cell count were carried out on blood samples taken on the last day before and the first day after HIPEC. White blood cell count, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and gamma-glutamyltransferase (γ -GT) were registered. TRNT was used as a measurement of the duration of post-operative ileus.

The temperature of the perfusate was measured in three locations: left and right in the upper abdomen, and in the pelvis. AUC was calculated separately for each registration location with a data summary model for repeated measures (baseline = 0) in Medcalc™ 12.5.0 (MedCalc Software, Acaciaaan 22, B-8400 Ostend, Belgium.) The mean AUC over the three locations was used in this study. The unit of AUC is °C*minute.

The full dataset is provided in the accompanying Data File. Blanks in these tables represent missing data.

Hyperthermic perfusion

Patients were placed in modified Lloyd Davies position and the upper body covered with a heating blanket (Bair Hugger, Arizant Healthcare Inc., Eden Prairie, MN, USA). Cytoreductive surgery aimed to remove all resectable implants of tumor while preserving the patient's quality of life. Following verification of resectability and absence of undetected metastatic disease, the entire colon was mobilized starting from the ileocolic region working towards the left. The major omentum was removed en bloc with the affected colon whenever it was involved in the disease process. The spleen, or pancreatic tail were included in the specimen when affected by cancer. A peritonectomy of the diaphragm was performed according to a previously described method²². When required, the tendinous part of the diaphragm was partially resected. Following the

resections in the upper abdomen, tumor tissue was removed from the pelvis. After that, the serosal surfaces covering the small bowel and mesentery were cleared from tumor tissue by a combination of tumorectomy, wedge resection, or segmental resection as required. At least 150 cm of small bowel had to be preserved. An open abdomen method was used for the administration of the intraperitoneal chemoperfusion, as described previously²³. The skin was sutured to a retractor frame placed over the abdomen. A plastic hood was positioned over the frame in order to allow the evacuation of vapor escaping from the abdominal cavity. Two Tenkhofttype inflow drains and three multiperforated outflow drains connected to a roller pump were used for chemoperfusion. The drains were placed in the pelvis, right upper abdomen and left upper abdomen. A heat exchanger was placed along the drains in order to maintain the required temperature. Hypothermia (34°C) was maintained prior to the start of chemoperfusion. Central temperature was monitored with an esophageal temperature probe. Abdominal temperature was monitored by means of three thermocouple probes placed left and right in the upper abdomen, and in the pelvis.

Prior to chemoperfusion, intravenous chemotherapy, consisting of folate 20 mg/m² followed by a 5-fluorouracil 400 mg/m² in 250 ml of saline perfusion over 1 hour, was administered to non-ovarian cancer patients according to standard procedures. Oxaliplatin (460 mg/m²) was added to the perfusion circuit when the abdominal temperature reached the set temperature. The duration of the chemoperfusion was 30 minutes. The abdominal cavity was not washed, in order to retain the efficacy of remaining drug. After the chemoperfusion, the abdomen was closed in layers.

Statistical analysis

The primary end-point of this study was overall survival. Overall survival was measured from the day of surgery till death. Patients who were alive at the last contact moment were censored at the date of last contact.

The secondary end-points were major complications, the occurrence of anastomotic leaks and TRNT. TRNT was a proxy variable for post-operative ileus. Univariate relations between Tmax or AUC and stay at ICU, total hospital stay, post-operative white blood cell count, AST, ALT, γ -GT and TRNT were explored by means of linear regression or negative binomial regression, as appropriate. Univariate relations between Tmax or AUC and overall survival were explored by means of Cox-regression.

A negative binomial regression model predicting TRNT was built using Tmax, AUC, sex, age at the time of the operation, operation time, stay at ICU, post-operative white blood cell count, AST, ALT and γ -GT as independent variables. The parameters “major complications” and “anastomotic leaks” are binary variables; therefore a logistic regression model was built to predict these outcomes, including Tmax, AUC, sex, age at the time of the operation, BMI, post-operative white blood cell count, AST, ALT and γ -GT, operation time and number of anastomoses as independent variables. A Cox proportional hazards model predicting overall survival was built using Tmax, AUC, sex, age at the time of the operation, operation time, number of anastomoses, tumor type, stay at ICU, total hospital

stay, post-operative white blood cell count, AST, ALT and γ -GT as independent variables. Backwards stepwise selection was used for model building. Statistical significance was assumed when $P < 0.05$.

Results

From July 2005 until February 2011, 138 patients were treated with oxaliplatinbased HIPEC in a tertiary center. Demographic data are illustrated in Table 1. Mean age was 59 years, ranging from 17 to 82 years (Figure 1). Forty-four percent of the patients were males. Nearly 60% of the patients presented with PC originating from colorectal cancer. Ovarian cancer and pseudomyxoma peritonei were the second and third most frequent cause of the PC, respectively.

Table 1. Demographic details of 138 patients treated with oxaliplatin based HIPEC (*:minimum-maximum).

Age (mean, years)	59	17–82*
Male / Female (%)	44/56	
BMI (mean)	24.1	16.8–34.1*
Synchronous / Metachronous disease (%)	35/65	
Histology (%)		
Colorectal	58	
Ovarian	12	
Pseudomyxoma peritonei	11	
Other	19

Figure 1. Distribution of age (years). Histogram of frequencies of ages of the included patients.

Figure 2. Distribution of duration of anaesthesia (minutes). Histogram of frequencies of the duration of anaesthesia in the included patients.

Figure 3. Distribution of maximal temperature (Tmax) (°C). Histogram of frequencies of maximal temperature of the included patients.

Details of the surgery are illustrated in Table 2. The mean anaesthesia time was nearly 10 h, ranging from 4 to 18 h and with a standard deviation of 2.8 h (Figure 2). On average, the maximal temperature was 40.5°C and the area under the temperature curve was 1340.63°C*minute (Figure 3 and Figure 4).

Outcome of surgery is summarized in Table 3. Two patients (1.4%) died within 30 days after the operation. Due to the small number of events the influence of AUC and maximal temperature on 30 days mortality could not be examined. Twenty-six patients needed reoperation. Reasons for reoperation were anastomotic leak (fourteen patients), intra-abdominal bleeding (five patients),

Figure 4. Distribution of area under the curve (°C*minutes). Histogram of frequencies of the AUC of the included patients.

Table 2. Details of surgery (Mean and Standard deviation).

Operating time (minutes)*	579	166
Number of anastomoses (%)		
0	35.5	
1	30.4	
2	25.4	
3	5.1	
4	2.2	
5	1.4	
Peak temperature (°C)*	40.510	1.143
AUC*	1340.63	91.63

Table 3. Outcome of surgery (* % of patients with at least one anastomosis ** Data represent median and range).

30-day mortality n (%)	2 (1.4)
Major complications n (%)	38 (27.5)
Anastomotic leaks n (%)	16 (18.0)*
Reoperation rate n (%)	26 (18.8)
Median ICU stay (days)	2 (0–87)**
Median hospital stay (days)	18 (3–169)**

perforation of the stomach (one patient), subobstruction (one patient), wound infection (one patient), bladder leak (one patient), and abdominal collection (three patients). In one patient, scald injuries were found during reoperation. Eighty-nine patients had at least one anastomosis, resulting in 155 anastomoses. Anastomotic leak occurred in sixteen patients. However, neither AUC nor Tmax was related to anastomotic leaks ($P=0.68$ and $P=0.67$, respectively) or major complications ($P=0.50$ and $P=0.20$, respectively).

A logistic regression model assessing the relation between several predictors and the occurrence of anastomotic leaks was fitted (Table 4). Longer operation time, a high number of anastomoses and post-operative leukocyte count were associated with the occurrence of leaks. Two variables describing the temperature during the operation were included in the model: Tmax and AUC. Both were close to significance. However, the effects of these variables were going in opposite directions: increasing AUC was associated with the occurrence of leaks, while increasing Tmax was associated with no leaks.

The number of anastomoses and the total operation time were associated with the occurrence of major complications (Table 5). Tmax and AUC were not related to the occurrence of major complications.

On average, patients stayed 4 days in the ICU (median 2, range 1 to 87, Figure 5). The total hospital stay was 27 days on average (median 18, range 3 to 169, Figure 6). The relationship between stay at ICU and Tmax or AUC is illustrated in Figure 7 and Figure 8, respectively. From these figures, it seems that patients with an extremely long stay at the ICU were treated at higher temperatures. In terms of the total hospital stay, there were fewer outliers and the duration was more evenly spread as a function of Tmax and AUC (Figure 9 and Figure 10).

On average, the nasogastric tube was removed after 7 days (median 5, range 0 to 77). The time to removal of the nasogastric tube seemed to remain constant with increasing temperature (Figure 11 and Figure 12). A model predicting the time to removal of nasogastric tube was fitted (Table 6). Four of the assessed variables turned out to be significantly related to TRNT: sex, Tmax, operation time and post-operative leukocyte count. On average, removal of the nasogastric tube was sooner after the operation in females than in males. With increasing maximal temperature, the expected TRNT decreased. Increasing post-operative leukocyte count and operation time was associated with an increased expected TRNT.

Median survival was 23 and 27 months in patients with PC from colorectal and ovarian origin, respectively (Table 7). In univariate analysis Tmax was significantly associated with hazard of death ($P=0.042$), while AUC was not significantly associated to this hazard ($P=1.117$) (Table 8).

A model predicting the hazard of death was built. Four of the considered variables turned out to be significantly related to this hazard: tumor type, sex, maximal temperature and operation time (Table 9). The expected hazard ratio for an increase of 1°C in maximal temperature was 1.6, with the other variables in the model kept at fixed values. The predicted survival curves from this model are presented in Figure 13 and Figure 14.

Table 4. Model predicting the odds ratio for no leaks versus leaks.

Variable	Estimate	SE	95% CI	Limits P
Intercept	0.8	15.9		
Number of anastomoses	-0.7	0.3	-1.4 to -0.1	0.03
AUC	-0.09	0.05	-0.18 to 0.01	0.07
Tmax	3.1	1.7	-0.1 to 6.4	0.06
Operation time	-0.0050	0.0025	-0.0098 to -0.0002	0.04
Post-operative leukocyte count	-0.2	0.1	-0.3 to -0.03	0.02

Table 5. Model predicting the odds ratio for no major complications versus major complications.

Parameter	Estimate	SE	95% CI	P
Intercept	3.2	0.8	1.6 to 4.9	<0.01
Number of anastomoses	-0.30	0.17	-0.64 to 0.05	0.09
Operation time	-0.003	0.001	-0.006 to -0.001	0.01

Figure 5. Distribution of stay at ICU (days). Histogram of frequencies of stay at ICU in the included patients.

Figure 6. Distribution of total hospital stay (days). Histogram of frequencies of duration of hospitalization in the included patients.

Figure 7. Stay at ICU (days) versus maximal temperature (°C). Scatterplot showing the relation between stay at ICU and Tmax.

Figure 8. Stay at ICU (days) versus area under the curve (°C*minutes). Scatterplot showing the relation between stay at ICU and AUC.

Figure 9. Total hospital stay (days) versus maximal temperature (°C). Scatterplot showing the relation between total hospitalization duration and Tmax.

Figure 10. Total hospital stay (days) versus area under the curve (°C*minutes). Scatterplot showing the relation between hospitalization duration and AUC.

Table 6. Model predicting the logarithm of time to removal of nasogastric tube (TRNT) (dispersion parameter 0.3 (95% CI 0.2 to 0.5), scaled deviance 94.9 on 88 degrees of freedom).

Variable	Estimate	SE	95% CI	P
Intercept	10.2	3.1	4.2 to 16.2	<0.001
Sex	-0.4	0.1	-0.6 to -0.1	0.02
Tmax	-0.2	0.08	-0.4 to -0.1	<0.01
Operation time	0.001	0.0005	0.0003 to 0.0020	0.01
Post-operative leukocyte count	0.03	0.01	0.008 to 0.061	0.01

Table 7. Survival (in months).

Primary tumor	Mean	95% CI	Median	95% CI
Colorectal	29	22–36	23	15–31
Ovarian	30	16–44	27	0–55

Table 8. Cox regression.

	P	Exp(B)	95.0% CI for Exp(B)
AUC	0.117	0.997	0.994–1.001
Tmax	0.042	1.306	1.010–1.688

The following analysis was not initially planned. An additional model predicting the hazard of death was built to evaluate the whether or not blood concentration of sodium, potassium, glucose, lactate, and pO_2 or pCO_2 during the operation were significantly related to post-operative survival. The variables from the first model were included as well. Tumor type, operation time, sex and lactate concentration in the blood were significantly associated with hazard of death (Table 10). The predicted survival curves from this model are presented in Figure 15. Tmax was not significantly associated with the hazard of death after blood lactate concentration was included in the model. This is probably due to high correlation between Tmax and lactate concentration (Figure 16).

Influence of perfusion temperature during hyperthermic intraperitoneal chemoperfusion on post-operative outcome and survival

2 Data Files

<http://dx.doi.org/10.6084/m9.figshare.730373>

Discussion

In selected patients, cytoreductive surgery combined with hyperthermic intraperitoneal chemoperfusion (HIPEC) results in a better survival compared with systemic chemotherapy²⁴. Major complications occur frequently in the post-operative period. Hyperthermia

Figure 11. Time to removal of nasogastric tube (TRNT) (days) versus Tmax (°C). Scatterplot showing the relation between TRNT and Tmax.

Figure 12. Time to removal of nasogastric tube (TRNT) (days) versus area under the curve (°C*minutes). Scatterplot showing the relation between TRNT and AUC.

Figure 13. Estimated survival (days) curves for patients with PC from colorectal origin. 1: males, 37°C; 2: males, 42°C; 3: females, 37°C; 4: females, 42°C. All at 579 minutes operation time (mean).

Table 9. Model predicting the logarithm of the hazard of death (HR: Hazard ratio; SE: Standard error).

Variable		Estimate	SE	P	HR	95% CI
Tumor type	Other	1.1	0.4	<0.01	3.0	1.3 to 6.6
	PMP	-0.9	0.6	0.2	0.4	0.1 to 1.5
	Ovarian	0.6	0.5	0.3	1.7	0.7 to 4.5
Sex		-0.5	0.4	0.1	0.6	0.3 to 1.2
Tmax		0.5	0.2	0.01	1.6	1.1 to 2.3
Operation time		0.003	0.001	<0.01	1.003	1.001 to 1.006

Table 10. Model predicting the logarithm of the hazard of death, after inclusion of metabolic variables (HR: Hazard ratio; SE: Standard error).

Variable		Estimate	SE	P	HR	95% CI
Tumor type	Other	1.4	0.5	<0.01	4.2	1.7 to 10.2
	PMP	-0.4	0.6	0.5	0.7	0.2 to 2.4
	Ovarian	0.6	0.6	0.3	1.9	0.6 to 5.9
Lactate		0.04	0.01	<0.01	1.04	1.02 to 1.1
Sex		-0.7	0.4	0.08	0.5	0.2 to 1.1
Operation time		0.003	0.001	0.01	1.003	1.001 to 1.006

Figure 14. Estimated survival (days) curves for patients with PC from ovarian origin. 1: 37°C; 2: 42°C. All at 579 minutes operation time (mean).

Figure 15. Estimated survival (days) curves for patients with PC from colorectal origin. 1: males, 37°C; 2: males, 40°C; 3: males, 42°C; 4: females, 37°C; 5: females, 40°C; 6: females, 42°C. All at 579 minutes operation time (mean) and 9.9 lactate mmol/l (mean).

is a possible risk factor for reduced anastomotic healing^{16–18}. There is currently no evidence for better survival in patients treated with hyperthermic chemoperfusion compared to normothermic chemoperfusion. The aim of this study was to analyze the effects of hyperthermia on post-operative survival and on the post-operative complications.

The data presented here show a statistically significant association between increasing temperature during the perfusion and decreasing post-operative survival. More precisely, the expected hazard ratio is 1.6 times as large for an increase of 1 degree in the temperature of the perfusion.

Maximal temperature was related to TRNT, with shorter TRNT for higher temperatures. The relation of temperature to the occurrence of anastomotic leaks was ambivalent. However, the results indicate the possibility of a negative effect of increasing temperatures on the occurrence of anastomotic leaks.

Survival analysis did show an inverse relation between Tmax and post-operative survival both in univariate and multivariate analyses.

Previously, in an animal model of PC a negative relation between survival and high temperature was also suggested as well¹⁹.

The present study has several limitations. First it is not randomized. Hyperthermia is the standard for intraperitoneal chemoperfusion. The temperature was adjusted to the clinical status of the patients. Normothermic chemoperfusion was administered in patients with important comorbidity. This may cause a bias. However, survival is worse in patients treated with perfusate with a higher temperature although these were the patients with less comorbidity. Second, it is a retrospective study; therefore the data were not acquired in a standardized way which again is a possible source of biases.

Given these limitations, it is too early for a final conclusion on the relationship between hyperthermia and survival in the setting of HIPEC. However, the significantly worse survival in patients treated with hyperthermic intraperitoneal chemotherapy HIPEC raises important concerns about the safety of this method. Although, in selected patients, the results of HIPEC seems to be better than standard therapy^{2,4}, treatment can possibly be further

Figure 16. Blood lactate concentration (mmol/l) versus maximal temperature (°C). Scatterplot showing the relation between blood lactate concentration and T_{max}.

improved by reducing the temperature during the chemoperfusion to body temperature (i.e. 37–38°C). Future research on HIPEC should focus on two aspects of the treatment. First, randomized studies comparing normothermic to hyperthermic chemoperfusion are needed. Second, the causal mechanism of the worse survival in patients treated with hyperthermic chemoperfusion should be clarified.

Consent

All data have been completely anonymised, without altering the scientific meaning of the analyses.

Author contributions

The author collected all the data, did the statistical analyses and wrote the article.

Competing interests

No relevant competing interests were disclosed.

Grant information

The author(s) declared that no grants were involved in supporting this work.

References

1. Jones H 3rd, Ngan HY, Pecorelli S, *et al.*: **FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO committee on gynecologic oncology.** *Int J Gynaecol Obstet.* 2000; **70**(2): 209–262.
[PubMed Abstract](#) | [Publisher Full Text](#)
2. Huang HQ, Baergen R, Lele S, *et al.*: **Intraperitoneal cisplatin and paclitaxel in ovarian cancer.** *N Eng J Med.* 2006; **354**(1): 34–43.
[PubMed Abstract](#) | [Publisher Full Text](#)
3. Brouquet A, Marchal F, Classe JM, *et al.*: **Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin.** *J Clin Oncol.* 2009; **27**(5): 681–685.
[PubMed Abstract](#) | [Publisher Full Text](#)
4. Bereder JM, Quenet F, Sideris L, *et al.*: **Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients.** *Cancer.* 2010; **116**(24): 5608–5618.
[PubMed Abstract](#) | [Publisher Full Text](#)
5. Sugarbaker PH, Jacquet P: **Peritoneal-plasma barrier.** *Cancer Treat Res.* 1996; **82**: 53–63.
[PubMed Abstract](#) | [Publisher Full Text](#)
6. Cowan DSM, Egorin MJ, Tannock IF, *et al.*: **Limited penetration of anticancer drugs through tumor tissue: A potential cause of resistance of solid tumors to chemotherapy.** *Clin Cancer Res.* 2002; **8**(3): 878–884.
[PubMed Abstract](#)
7. Chau I, Cunningham D: **Adjuvant therapy in colon cancer—what, when and how?** *Ann Oncol.* 2006; **17**(9): 1347–1359.
[PubMed Abstract](#) | [Publisher Full Text](#)
8. Ferron G, Rigaud DB, Bourbouloux E, *et al.*: **Oxaliplatin-based hyperthermic intraperitoneal chemotherapy in primary or recurrent epithelial ovarian cancer: a pilot study of 31 patients.** *J Surg Oncol.* 2011; **103**(1): 10–16.
[PubMed Abstract](#) | [Publisher Full Text](#)
9. Iveson T, Nicolson M, Coxon F, *et al.*: **Capecitabine and oxaliplatin for advanced esophagogastric cancer.** *N Eng J Med.* 2008; **358**(1): 36–46.
[PubMed Abstract](#) | [Publisher Full Text](#)
10. Shea MT, Evans MT, Goonewardene TI, *et al.*: **Phase II trial of vinorelbine and oxaliplatin as first line therapy in malignant pleural mesothelioma.** *Lung Cancer.* 2005; **47**(2): 277–281.
[PubMed Abstract](#) | [Publisher Full Text](#)
11. Milano G, Lvi F, Massari C: **Oxaliplatin: Pharmacokinetics and chronopharmacological aspects.** *Clin Pharmacokinet.* 2000; **38**(1): 1–21.
[PubMed Abstract](#)
12. Mella O, Akslen L, Bruland O, *et al.*: **Hyperthermia improves the antitumor effect of metronomic cyclophosphamide in a rat transplantable brain tumor.** *Radiother Oncol.* 2008; **86**(3): 435–442.
[PubMed Abstract](#) | [Publisher Full Text](#)
13. Xu G, Ngai C, Fung K, *et al.*: **Apoptotic and necrotic effects of tumor necrosis factor- α potentiated with hyperthermia on I929 and tumor necrosis factor- α -resistant I929.** *Int J Hyperthermia.* 2010; **26**(6): 556–564.
[PubMed Abstract](#) | [Publisher Full Text](#)
14. Tamm M, Szilard J, Roth M, *et al.*: **Mesothelioma cells escape heat stress by upregulating hsp40/hsp70 expression via mitogen-activated protein kinases.** *J Biomed Biotechnol.* 2009; **2009**: 451084.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
15. Sideris L, Pichette V, Drolet P, *et al.*: **Rationale for heating oxaliplatin for the intraperitoneal treatment of peritoneal carcinomatosis: a study of the effect of heat on intraperitoneal oxaliplatin using a murine model.** *Ann Surg.* 2011; **254**(1): 138–144.
[PubMed Abstract](#) | [Publisher Full Text](#)
16. Decker M, Dimmler A, Hohenberger W, *et al.*: **Hyperthermic intraperitoneal chemoperfusion (HIPEC) decrease wound strength of colonic anastomosis in a rat model.** *Int J Colorectal Dis.* 2007; **22**(8): 941–947.
[PubMed Abstract](#) | [Publisher Full Text](#)
17. Man BD, Lomme R, Boerman O, *et al.*: **The effects of adjuvant experimental radioimmunotherapy and hyperthermic intraperitoneal chemotherapy on intestinal and abdominal healing after cytoreductive surgery for peritoneal carcinomatosis in the rat.** *Ann Surg Oncol.* 2008; **15**(11): 3299–3307.
[PubMed Abstract](#) | [Publisher Full Text](#)
18. Koga S, Shimizu T, Maeta M: **Inuence of local hyperthermia on the healing of small intestinal anastomoses in the rat.** *Brit J Surg.* 1991; **78**(1): 57–59.
[PubMed Abstract](#) | [Publisher Full Text](#)
19. Rutten HJT, Bleichrodt RP, de Hingh IHJT, *et al.*: **Hyperthermia and intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis: an experimental study.** *Ann Surg.* 2011; **254**(1): 125–130.
[PubMed Abstract](#) | [Publisher Full Text](#)
20. Shen P, Stewart JH, Levine EA, *et al.*: **Survival and quality of life following cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of colonic origin.** *Ann Surg Oncol.* 2011; **18**(13): 3673–3679.
[PubMed Abstract](#) | [Publisher Full Text](#)
21. Chua T, Morris D, Saxena A, *et al.*: **Critical assesment of risk factors for complications after cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei.** *Ann Surg Oncol.* 2010; **17**(5): 1291–1301.
[PubMed Abstract](#) | [Publisher Full Text](#)
22. Sugarbaker P: **Peritonectomy procedures.** *Ann Surg.* 1995; **221**(1): 29–42.
[PubMed Abstract](#) | [Free Full Text](#)
23. Edwards GD, Esquivel J, Sebbag G, *et al.*: **Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique.** *Ann Surg Oncol.* 1999; **6**(8): 790–796.
[PubMed Abstract](#)
24. Yan TD, Savady R, Sugarbaker PH: **Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma.** *J Clin Oncol.* 2006; **24**(24): 4011–4019.
[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:

Version 1

Reviewer Report 08 January 2014

<https://doi.org/10.5256/f1000research.867.r3009>

© 2014 Kusamura S. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Shigeki Kusamura

Department of Surgery, Fondazione IRCCS Istituto Nazionale Tumori Milano, Milan, Italy

The author evaluated the correlation of temperature during HIPEC with short-term surgical and long term oncologic outcomes in patients affected by several types of peritoneal carcinomatosis. The idea is interesting, the paper reasonably well-written, and the analysis conducted meticulously.

The temperature was appraised using two parameters: Tmax and AUC.

- The first caveat of the paper is Tmax. If there is a possibility of tissue damage exerted by the heat, the negative effect depends not only on the level of temperature but also on the duration of the exposure to hyperthermic conditions. Under 43°C it is hard to observe significant tissue damage if the exposure does not last more than 30 minutes, according to experimental data. Therefore, in my opinion, this parameter is not suitable and unreliable to achieve the objectives of the study.
- The second weak point is the survival analysis. Important parameters such as PCI, completeness of cytoreduction, tumor grade, lymph node status (for colon cancer), and whether the tumor is primary or relapsing, the platinum sensitivity (for ovarian cancer) were not considered in the cox model. Moreover, in figure 13 the events occurred at the same time points from the surgery in all four subsets. Is that a coincidence? In the figure 14 groups 1 and 2 combined had 46 events (deaths). How could you explain if the total number of ovarian cases were 16 cases?
- The tables outlining logistic regression analysis could be better presented by changing the Estimates by Odds Ratio. Remember, $OR = \exp(B) = e^{\text{estimate}}$

My advice is to reconsider the Tmax and survival analysis. Even though these parts contain the only significant correlations, I myself would take them out from the study. The correlations with short-term surgical outcome is sufficiently interesting to justify the publication.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Reviewer Report 08 November 2013

<https://doi.org/10.5256/f1000research.867.r2235>

© 2013 **Piso P.** This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Pompiliu Piso

University of Regensburg, Regensburg, Germany

This article is investigating the role of perfusion temperature on postoperative outcome and survival of patients with peritoneal carcinomatosis. The idea is interesting, however, the presented data does not support the conclusions.

The analysis was retrospective, the time interval very long, monocentric with a bias regarding surgeons, used technique and chemotherapy regime (mixed patients with HIPEC alone or plus intravenous 5FU).

The postoperative outcome is determined mainly by the extent of surgery and critical anastomosis and less by HIPEC itself. This has been shown by several published data. The TRNT is influenced by even more other factors. The causality relation between the maximal temperature and survival has not been demonstrated. Moreover, other significant prognostic factors e.g. peritoneal cancer index, completeness of cytoreduction, histologic subtype etc have not been evaluated. Out of any context, temperature may play in the statistical analysis a role but the clinical interpretation of the results should be very careful. For instance, who were the patients having maximal temperature during HIPEC: was this group having a high tumor load with a high Peritoneal Cancer Index?, a more difficult resection, were they co-morbid etc.

In my opinion, this manuscript is confusing rather than helpful. We know from other hyperthermia studies that efficacy is affected by every °C – this sounds more reasonable to me.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to state that I do not consider it to be of an acceptable scientific standard, for reasons outlined above.

Author Response 13 Jan 2014

Johanna Verhulst, Karel Oomsstraat 57, Antwerpen, Belgium

I am fully aware of the limitations due to the retrospective nature of the study. The intention of the study was to be a pilot study concerning the effects of hyperthermia in the context of HIPEC. The study does not claim to be able to draw any final conclusions on a causal relation between hyperthermia and post-operative survival. However, a negative correlation between those variables was observed. As it is not possible to make any final inference about this matter based on this study, further randomized studies should be conducted in order to confirm or disprove the results from this study.

As mentioned in the article, the patients treated with lower temperatures, were the patients with higher co-morbidity. Nevertheless, these patients had a longer survival in the studied population. Therefore, it could be expected that in a randomized study, the negative effect would be even bigger.

I would be grateful for references to articles studying the effects of hyperthermia on post-operative outcome.

Competing Interests: No competing interests were disclosed.

Reviewer Report 01 October 2013

<https://doi.org/10.5256/f1000research.867.r1679>

© 2013 L Morris D. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

David L Morris

Department of Surgery, University of New South Wales, NSW, Australia

This article certainly made me sit up and think. The finding of an adverse effect of $T_{\max}$ during HIPEC on long term survival is certainly very challenging. The science of the effects of hyperthermic intraperitoneal chemoperfusion is far from solid, but we have achieved previously unachievable survival results by using it. If this article is correct, we are harming our patients by using heat. I do not have the best statistical brain in the world, but the number of patients is small and for example there are only 21/138 patients with a maximum temperature of $<39.5^{\circ}\text{C}$ and only 10/138 with a temperature $>41.5^{\circ}\text{C}$. The model used in figures 13 and 14 may well be valid but when there are only one or two patients with a $T_{\max}$ of 37°C it is not appropriate to plot a survival curve. The lactate data is interesting because it provides a clear illustration that a biologically important measure is being affected by temperature.

This paper creates more questions than answers but is clearly a stimulus to others to examine their data.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Comments on this article

Version 1

Author Response 01 Oct 2013

Johanna Verhulst, Karel Oomsstraat 57, Antwerpen, Belgium

One of the referees has requested that extra data plots should be made available as part of the article; two additional plots were created.

The first one shows the actual survival curve (with 95% CI) for all 11 patients treated with maximal temperature below 39°C.

The second one shows the actual survival curve (with 95% CI) for 5 patients treated with maximal temperature below 39°C and primary tumour of colorectal origin.

The plots and data from which they were generated can be found here:

<http://testbc.figshare.com/verhulst/>

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research